Lynx Financial

Bone Index Finland Ltd. is a company specializing in osteoporosis diagnostics, founded in 2011 and headquartered in Kuopio, Finland. The company's primary product, Bindex, is a device designed to measure multisite cortical bone thickness, which aids in diagnosing osteoporosis in accordance with international guidelines. Unlike traditional DXA devices typically found in hospitals, Bindex offers a quick and simple method for assessing bone health by measuring the cortical thickness of the tibia. This information, when combined with other patient data, allows for the estimation of bone mineral density in the hip region. Bindex's efficiency makes it suitable for large-scale screenings of high-risk groups, enabling earlier identification of osteoporosis risk before fractures occur. This proactive approach not only enhances patient quality of life but also contributes to reducing public healthcare costs.

Elucida Oncology, Inc. is a biotechnology company that specializes in developing innovative cancer therapies through its nanoparticle drug delivery platform. This platform, known as the Target/Clear C-Dot, utilizes ultra-small cancer-targeting particles designed for diagnostic imaging, surgical procedures, and therapeutic applications. The C-Dots, which encapsulate near-infrared dye within a rigid silica shell, are engineered to specifically target cancer cells and are efficiently cleared from the body via the renal system. Elucida's technology is aimed at enhancing the detection and treatment of both primary solid tumors and metastatic cancers, while minimizing off-target toxicities and improving patient safety. Founded in 2014 and headquartered in Monmouth Junction, New Jersey, Elucida Oncology is committed to transforming patient outcomes through precise tumor targeting and effective treatment strategies.

Aurealis Therapeutics is focused on developing innovative solutions for non-healing wounds and complex inflammatory diseases. The company is advancing its four-in-one biologic drug, AUP-16, which aims to offer faster and more complete healing. By the end of 2022, Aurealis Therapeutics planned to demonstrate solid clinical efficacy data in diabetic foot ulcers and establish proof-of-concept data for other inflammatory conditions. Their cell and gene therapy platform represents a novel combination immunotherapy approach, designed to efficiently and cost-effectively activate and modulate the innate immune system. Through these advancements, Aurealis Therapeutics seeks to engage with strategic partners, ensuring that their transformative technology can benefit millions of patients.